“I am dedicated to revolutionizing jaundice management. In collaboration and support of the neonatal and pediatric medical community, we envision a paradigm shift from treating hyperbilirubinemia based on total serum bilirubin levels to a future in which we employ ETCOc analysis to identify and treat newborns suffering from abnormally high production of neurotoxic bilirubin. This transformative approach will prevent unnecessary blood testing and treatment, reduce delayed or missed diagnoses, and ensure timely treatment for those at risk of BIND and kernicterus. Together, we can create a future where every newborn receives precise and personalized care for jaundice.”
In 2017, Capnia acquired the CoSense® ETCOc Monitor's intellectual property, an innovation powered by Sensalyze™ Technology, from Soleno Therapeutics. Since the strategic acquisition, Capnia’s dedicated team has taken significant strides in advancing the technology, conducting rigorous validation processes, and is now commercializing this revolutionary technology to improve jaundice management in newborns. With a team of seasoned experts in both business and clinical fields, Capnia is dedicated to advancing healthcare through innovation, aiming to positively impact infants, neonates, and families globally by elevating care standards.
Dr. Bahr is a neonatologist and Assistant Professor of Pediatrics at Intermountain Health and the University of Utah. Dr. Bahr completed medical school at the University of Iowa and his pediatrics residency at Phoenix Children's Hospital. He completed his fellowship in neonatology and neonatal hematology with Drs. Robert Christensen and Robin Ohls at the University of Utah in Salt Lake City, UT. Dr. Bahr’s research and clinical interests are in hematologic disorders of neonates. He has published extensive clinical and translational research in areas such as (1) the management and diagnosis of neonates with hyperbilirubinemia; (2) preventing, detecting, and managing iron deficiency in preterm neonates; and (3) improving neonatal transfusion practices.
Dr. Anthony E. Burgos, MD, MPH is the Co-Founder and President of Bilitool, Inc., the most widely used website for the management of hyperbilirubinemia in newborns. He is the Co-Founder and former Managing Director of the Better Outcomes for Newborns (BORN) research network of the Academic Pediatric Association. He is currently an Associate Professor of Clinical Science and Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine. He is widely published in the areas of newborn jaundice and newborn standards of care. He is committed to identifying and integrating innovation, building consensus, and improving practice standards to make a measurable difference in healthcare.
Dr. Christensen, a pro bono advisor, is the Director of Neonatal Research at Intermountain Healthcare and Director of the Intermountain Healthcare Clinical Neonatology Program for the northern region, where the majority of his research work is focused on observational and interventional clinical studies of neonatal clinical hematology and transfusion medicine. Dr. Christensen held positions including Professor of Pediatrics at the University of Utah School of Medicine, the University of Florida College of Medicine, and the University of South Florida College of Medicine, and was Physician-in-Chief at All Children’s Hospital in St. Petersburg, Florida. He has been a member of the NIH National Heart, Lung and Blood Institute, NIH National Institute of Child Health and Human Development, and National Foundation March of Dimes, was on the executive committee of Thrasher Research Fund, and was sub-committee chair of the American Academy of Pediatrics. He has authored over 300 publications.
Dr. Schutzman is a neonatologist at Jefferson Einstein Medical Center in Philadelphia. Dr. Schutzman completed medical school, a Pediatric residency, and a fellowship in Neonatal-Perinatal Medicine at Jefferson Medical College. While his career has primarily been clinical in nature, he has published on multiple topics relevant to newborns. Most recently, he has focused his research on hyperbilirubinemia of the newborn and its management.
Dr. David K. Stevenson, MD, is the Harold K. Faber Professor of Pediatrics and has made many impactful contributions to the field of pediatrics. As a neonatologist, his research has focused primarily on neonatal jaundice, with special expertise in carbon monoxide detection for estimating total bilirubin production, and more recently on the causes of preterm birth and its prevention. He has held numerous leadership roles at Stanford University School of Medicine, including Vice Dean and Senior Associate Dean for Academic Affairs, Senior Associate Dean for Maternal & Child Health, Co-Director of the Stanford Maternal & Child Health Research Institute, Co-Director of the Metabolic Health Center, and Principal Investigator for the March of Dimes Prematurity Research Center at Stanford University. Dr. Stevenson has received many awards, including the Virginia Apgar Award, the highest award in Perinatal Pediatrics, the Joseph W. St. Geme, Jr. Leadership Award from the Federation of Pediatric Organizations, the Jonas Salk Award for Leadership in Prematurity Prevention from the March of Dimes Foundation, and the John Howland Medal and Award, the highest award given by the American Pediatric Society. He has served as the President of the American Pediatric Society. In recognition of his achievements, Dr. Stevenson is a member of the National Academy of Medicine.
